IL2 and neoplasm: The combination of therapy with NK cell-stimulating cytokines (IL-2, IL-12, IL-15 and IL-21), reagents against activities limiting NK cell functionality (anti-KIR/anti-PD1 monoclonal antibodies, Treg depletion) and reagents enhancing tumor cell recognition (monoclonal antibodies, bi/trispecific targeting reagents, chimeric antigen receptors) may hold promise in future NK cell-mediated antimetastatic therapy [290] (Figure 2).